Chief Executive Officer
Mr. Rongen is the Chief Executive Officer and a Co-Founder of Matinas BioPharma. He is also the Founder and Chairman of Essential Fatty Acid Therapeutics, a biotech company focused on the development of innovative fatty acid derivatives. Prior to Matinas BioPharma, Mr. Rongen was Executive Vice President North American Operations for EPAX/Trygg Pharma and Vice President of Life Cycle Management and Intellectual Property at Reliant Pharmaceuticals, a GlaxoSmithKline subsidiary. While at Reliant, Mr. Rongen held various earlier positions, including head of the Omacor®/Lovaza® launch team, Executive Director of Marketing for Lescol® and Executive Director of Business Development. Before Reliant, Mr. Rongen was Global Product Director for Humira® at BASF Pharmaceuticals, later acquired by Abbott. He was also a consultant at The Wilkerson Group in New York and with Arthur D. Little in Amsterdam. Mr. Rongen earned an MBA from Kellogg GSM at Northwestern University, and a graduate degree in Molecular Sciences from Wageningen Univerisity in the Netherlands.
Jerome D. Jabbour, Esq.
Mr. Jabbour is a Co-Founder and President of Matinas BioPharma since March 2016. Prior to that, he served as Executive Vice President, Chief Business Officer and General Counsel since October 2013. Mr. Jabbour has extensive experience in the pharmaceutical and healthcare industries, both domestically and internationally. Previously he served as Executive Vice President, General Counsel & Secretary of MediMedia, a diversified health care services company. Prior to MediMedia, he was the Senior Vice President and Head of Global Legal Affairs for Wockhardt Limited, a global pharmaceutical and biotechnology company. Immediately prior to that, he served as Commercial Counsel and Assistant Secretary for Reliant Pharmaceuticals, a GlaxoSmithKline subsidiary. Earlier in his career, he held positions as counsel at Alpharma and in private practice at Lowenstein Sandler, PC. Mr. Jabbour earned his J.D. from Seton Hall University School of Law in Newark, New Jersey and a B.A. in Psychology from Loyola University in Baltimore, Maryland.
Abdel A. Fawzy, Ph.D.
EVP, Pharmaceutical & Supply Chain Development
Dr. Fawzy is Executive Vice President for Pharmaceutical and Supply Chain Development and a Co-Founder of Matinas BioPharma. Prior to Matinas BioPharma, Dr. Fawzy was a co-founder of expert consulting firm DeMelle BioPharma and Executive Director Pharmaceutical Development at Reliant Pharmaceuticals, a GlaxoSmithKline subsidiary. Earlier in his career, Dr. Fawzy held pharmaceutical development positions at Ascent Pharmaceuticals, DuPont Pharma and Squibb Marsam Pharmaceuticals. He is the inventor of 15 published patents and patent applications all related to health care products and pharmaceutical development and associated manufacturing processes. Dr. Fawzy received his Ph.D. in Pharmaceutical Technology from Tuebingen University in Germany, a Pharmacy degree from Temple University in Philadelphia, and a MS in Pharmaceutical Technology from the Cairo School of Pharmacy in Egypt. Dr. Fawzy has completed a postdoctoral fellowship in Biochemistry at Medical College of Virginia.
Raphael J. Mannino, Ph.D.
Chief Scientific Officer
Dr. Mannino is an internationally recognized expert in the use of artificial lipid-based structures for the formulation and delivery of biologicals and pharmaceuticals, and has pioneered the use of cochleate technology for this purpose. He is a co-inventor of the proprietary, disruptive lipid-crystal nano-particle cochleate technology utilized by Matinas BioPharma to encapsulate existing drugs, making them safer, more tolerable, less toxic and orally available. Dr. Mannino has been a member of Matinas BioPharma's Scientific Advisory Board since January 2015 and was an Associate Professor of Pathology and Laboratory Medicine at Rutgers University, New Jersey Medical School from 1990 until August 2015.
Previously, Dr. Mannino was the founder of BioDelivery Sciences, Inc., and served as its President, Chief Executive Officer and Chief Scientific Officer and as a member of its Board of Directors from 1995 to 2000, when it was acquired by BioDelivery Sciences International, Inc. (BDSI). He served as BDSI's Executive Vice President and Chief Scientific Officer from 2001 to 2009, and was a member of its Board of Directors from 2000 to 2007. In addition to his experience at BDSI, Dr. Mannino was an Assistant, then Associate Professor, at Albany Medical College from 1980 to 1990, and an Instructor then Assistant Professor at Rutgers Medical School from 1977 to 1980. He completed his postdoctoral training from 1973 to 1976 at the Biocenter in Basel, Switzerland and received his Ph.D. in Biological Chemistry in 1973 from the Johns Hopkins University, School of Medicine.
Douglas F. Kling
Senior Vice President, Clinical Development and Project Management
Mr. Kling joined Matinas BioPharma as our Senior Vice President of Clinical Development & Project Management in March 2015. Prior to joining Matinas, Mr. Kling was Senior Vice President of Clinical Operations & Project Management at an AstraZeneca Company, Omthera Pharmaceuticals, where he worked from 2010 until 2014. Mr. Kling spearheaded the development of Epanova®, which was approved by the FDA in 2014. Prior to that Mr. Kling served as Senior Director of Project Management from July 2009 until July 2010 at Shionogi USA, a leading Japanese pharmaceutical company and as Senior Director of Program Management at The Medicines Company, an acute care company focused on cardiovascular diseases and anti-infectives, where he worked from April 2008 until July 2009. At both of these companies Mr. Kling took the leadership role in development for key portfolio products. For the bulk of his career, Mr. Kling worked at Reliant Pharmaceuticals (2000-2008) where he had increasing project management responsibilities for drug development programs in the metabolism/cardiovascular space in addition to antivirals and drugs for gastrointestinal disorders. Early in his career, Mr. Kling was a CRA at Kendle International (1996-1998) and clinical research manager Knoll Pharmaceutical Company (1998-2000), where he managed phase I-III studies for Humira®. In total Mr. Kling has spent over 18-years working on the development side of the pharmaceutical business. During this time he has worked on numerous NDAs and supplemental filings, which resulted in drug approvals and/or label modifications. Mr. Kling is a certified project management professional (PMP) by the Project Management Institute. In addition, he has an MBA from Rutgers Business School and a BS degree in biological sciences from Duke University.
Gary Gaglione, CPA
VP Finance, Acting-CFO
Mr. Gaglione joined Matinas BioPharma as Vice President of Finance in June 2013. Mr. Gaglione was formerly President of MCM Consulting LLC. In this capacity, he served as the interim CFO and Corporate Secretary of GTech USA Inc. Prior to MCM Consulting, Mr. Gaglione was Senior Director of Finance at Shionogi USA, Inc., responsible for budgeting and planning (2011). In 2009 and 2010, he was Vice President of Finance and Controller for Phytomedics, Inc., a start-up botanical pharmaceutical company. Prior to Phytomedics, he was Controller for ProStrakan Inc.'s U.S. operations (2008-2009). From 2001 to 2008, Mr. Gaglione was an Executive Director at Reliant, initially as head of Planning, Budgets and Analysis, then, from 2006 on, as head of Internal Audit and Sarbanes Oxley Compliance in preparation for a potential Reliant initial public offering. Before Reliant, he held numerous finance positions of increasing responsibility at the U.S. subsidiary of Hoffmann-La Roche Inc. (1976-2001), including Vice President of R&D Finance (1997-2001), Director of Compensation with responsibility for executive payroll, payroll, benefits, and exempt/non-exempt compensation systems (1995-1997), and Controller for the US pharmaceutical division and sites (1985-1997). He started his finance career at KPMG LLP (1974-1976). Mr. Gaglione earned a B.S. degree in Business Administration with a major in Accounting from Villanova University, Villanova, PA, and an MBA in Finance from Seton Hall University, West Orange, NJ.